Cardioprotective effect of taurine and β-alanine against cardiac disease in myocardial ischemia and reperfusion-induced rats
PDF

Keywords

Cardiac diseases
Cardio-protective
Docking
Infarct
Inflammatory markers
Ischemia
Lipid peroxidation
Rats
ROS
Taurine

How to Cite

1.
Hou X, Sun G, Guo L, Gong Z, Han Y, Bai X. Cardioprotective effect of taurine and β-alanine against cardiac disease in myocardial ischemia and reperfusion-induced rats. Electron. J. Biotechnol. [Internet]. 2020 Aug. 17 [cited 2024 Sep. 20];45. Available from: https://preprints.pucv.cl/index.php/ejbiotechnology/article/view/2020.04.003

Abstract

Background: The present study analyzed the synergistic protective effect of β-alanine and taurine against myocardial ischemia/reperfusion. Myocardial infarct size, lipid peroxidation, and levels of glutathione peroxidase (Gpx), superoxide dismutase (SOD), reduced glutathione (GSH), catalase, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), reactive oxygen species (ROS), apoptosis, and the mRNA and protein expression of Janus kinase 2 (JAK2) and signal transducer and activator 3 of transcription (STAT3) were determined. The molecular docking was carried out by using AutoDock 4.2.1.

Results: Combined treatment with β-alanine and taurine reduced myocardial infarct size, lipid peroxidation, inflammatory marker, ROS levels, and apoptosis and increased Gpx, SOD activity, GSH, and catalase activity. Furthermore, combined treatment significantly reduced JAK2 and STAT3 mRNA and protein expression compared with the control. The small molecule was docked over the SH2 domain of a STAT3, and binding mode was determined to investigate the inhibitory potential of β-alanine and taurine. β-Alanine bound to SH2 domain with ΔG of -7.34 kcal/mol and KI of 1.91 μM. Taurine bound to SH2 domain with ΔG of -7.38 kcal/mol and KI of 1.95 μM.

Conclusion: Taken together, these results suggest that the combined supplementation of β-alanine and taurine should be further investigated as an effective therapeutic approach in achieving cardioprotection in myocardial ischemia/reperfusion. 

PDF

Upon acceptance of an article by the journal, authors will be asked to transfer the copyright to Electronic Journal of Biotechnology, which is committed to maintain the electronic access to the journal and to administer a policy of fair control and ensure the widest possible dissemination of the information. The author can use the article for academic purposes, stating clearly the following: "Published in Electronic Journal of Biotechnology at DOI:10.2225/volXX-issueX-fulltext-XX".

The Copyright Transfer Agreement must be submitted as a signed scanned copy to biotec@ucv.cl. All authors must send a copy of this document.